Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
CorVel Corporation marks its 35th year on the Nasdaq, showcasing a history of strategic technology investments and operational excellence. The company emphasizes its strong financial position, commitment to innovation in healthcare management technologies, and readiness to continue delivering long-term value.
Microchip Technology has introduced its XpressConnect PCIe 6.0 and CXL 3.1 retimers designed to extend signal reach and reduce latency in AI data centers. These retimers support higher bandwidth connectivity and lower pin-to-pin latency, enabling better utilization of GPUs and AI accelerators in large-scale AI workloads. Integrated with Microchip's…
Lifecore Biomedical has signed a manufacturing services agreement with a leading ophthalmic disease solutions provider to conduct process development and technical transfer in preparation for potential commercial manufacturing of a next-generation injectable ophthalmic product. This marks the company's sixth addition to its late-stage pipeline in s…
Dollar General raised its fiscal 2026 earnings per share forecast and reiterated same-store sales guidance as consumers continue to favor lower-priced household goods. The company updated its EPS range higher while noting it did not include potential tariff refund payments in the outlook. Broader consumer budgets face headwinds from rising gasoline…
Ocugen, Inc., a biotechnology company specializing in gene therapies for blindness diseases, announced its participation in several investor and industry conferences in June 2026. The company will present its innovative modifier gene therapy platform targeting inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and geographi…
Pasithea Therapeutics announced that the FDA has granted Orphan Drug Designation to its drug candidate PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the company's efforts in developing PAS-004 for ALS and potentially other MAPK pathway-related diseases, providing benefits such as tax credits, fee exemptions, an…
Credo (CRDO) sold off after recent earnings, creating a tactical buying opportunity. The company sits at the center of AI infrastructure: high-speed SerDes, integrated circuits and active electrical cables. Despite stretched multiples - P/E ~122x and EV/sales ~38x - 202% YoY top-line growth reported in coverage and $283.7M of free cash flow give th…
Picard Medical, Inc., through its subsidiary SynCardia Systems, announced successful acute in vivo implant studies of its next-generation Emperor Total Artificial Heart (TAH). The studies demonstrated stable hemodynamic support and physiologic autoregulatory behavior in a large animal model, validating the independent dual motor ventricular design.…
Can-Fite BioPharma reports encouraging clinical observations from its Phase 2a pancreatic cancer study with its lead drug candidate Namodenoson, which exhibits a unique multi-pathway RAS signaling inhibition mechanism. The company underscores the importance of targeting KRAS-driven pancreatic ductal adenocarcinoma and notes prolonged disease contro…
Rezolute, Inc. announced positive interim data from its Phase 3 open-label upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI). With 8 participants enrolled (halfway to full enrollment), 6 have met the primary endpoint of at least 50% reduction in intravenous glucose requirements, and all were able to discontinue IV glucos…
ODDITY Tech Ltd. reported a 26% decline in first quarter 2026 net revenue to $197.9 million and an adjusted EBITDA loss of $7.0 million, impacted by a significant increase in customer acquisition costs (CPA) with its largest advertising partner. The company is actively working on remediation efforts and sees early signs of improvement in May 2026. …
Kodiak AI, a Nasdaq-listed company specializing in AI-powered autonomous vehicle technology, has been named to Inc.'s 2026 Best Workplaces list, highlighting its exceptional company culture and commitment to employee development. The accolade underscores Kodiak's position as a leader in autonomous trucking technology, advancing safer and more effic…
Lumexa Imaging (NASDAQ: LMRI), a leading outpatient imaging provider, announced a strategic joint venture with Hospital for Special Surgery (HSS), a world leader in musculoskeletal health. This marks Lumexa's ninth joint venture and aims to broaden access to advanced outpatient imaging services in the New York metro area. The partnership leverages …
X-energy has submitted its Xe-100 high temperature gas-cooled reactor (HTGR) design to the UK's Generic Design Assessment process, a key regulatory step towards licensing advanced nuclear technology in the UK. This submission supports plans to deploy up to 6 GW of nuclear capacity in partnership with Centrica, aiming to enhance UK energy security w…
SOLV Energy has announced its involvement in multiple large-scale solar and battery energy projects across the U.S., totaling more than 4 gigawatts in capacity. This marks a significant scale-up in projects exceeding 600 MWdc, with a diverse geographic footprint and integrated energy infrastructure offerings, underscoring the company's leadership a…
Aya Gold & Silver Inc. announced high-grade silver intercepts from its 2026 exploration drill program at the Zgounder Silver Mine in Morocco. Results demonstrate strong continuity of silver mineralization both near the open pit and at depth, supporting the potential for resource expansion. Drilling near the Western Fault and along the granite conta…
iBio has initiated dosing in its Phase 1 clinical trial for IBIO-600, a long-acting monoclonal antibody aimed at preserving muscle and improving body composition in adults with obesity. This milestone marks the company's transition to a clinical-stage biotech firm, showcasing progress in its AI-driven discovery platform and potential combination wi…
Telix Pharmaceuticals Limited (TLX) and United Imaging Healthcare North America have signed a Memorandum of Understanding to collaborate on the integration of Telix's molecular imaging products with United Imaging's advanced scanner platforms and AI capabilities. The initial focus will be on the US evaluation of TLX101-Px, a PET imaging candidate u…
Victoria's Secret & Co. delivered a robust first quarter 2026 performance, with net sales rising 15% to $1.56 billion, surpassing guidance. Operating income increased significantly to $76 million from $20 million a year prior, supported by strong sales growth across key brands and improved gross margins. The company raised its full-year 2026 net sa…
Vera Therapeutics announced alignment with the U.S. FDA on an earlier eGFR analysis for the ORIGIN Phase 3 trial of atacicept, a therapy targeting BAFF and APRIL for adults with IgA nephropathy (IgAN). The revised analysis is now planned for Q3 2026, ahead of the previous 2027 timeline. Pending positive results, the company plans to submit a supple…
BeyondSpring reported updated positive efficacy and safety results from its ongoing Phase 2 303 Study evaluating Plinabulin combined with pembrolizumab and docetaxel in metastatic non-small cell lung cancer patients who progressed after first-line immune checkpoint inhibitor therapy. The combination demonstrated favorable progression-free survival,…
Bioventus Inc. announced that CFO Mark Singleton will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The company, a leader in active healing innovations, will webcast the presentation live and replay it for investors. Bioventus focuses on products for pain treatment, restorative therapies, and surg…
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 at an increased dose of 10 mg/kg in their ongoing Phase 1/2 ELEVATE-45-201 clinical trial for ENTR-601-45, a potential treatment for Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. Cohort 1 participants have mo…
Opus Genetics, a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced a virtual R&D Science Forum on June 16, 2026. The forum will feature expert speakers discussing the company's multi-asset gene therapy pipeline, including upcoming clinical trials targeting RDH12, MERTK, and RHO mutations, r…
Fury Gold Mines Limited announced final assay results from Phase 1 and initial results from Phase 2 infill and expansion drilling programs at its Eau Claire gold project in Quebec. Significant intercepts confirm continuity and expansion of high-grade gold mineralization, supporting efforts to upgrade inferred resources to indicated categories ahead…
